Figure 6. This figure illustrates the current means of targeting the biologic processes promoting cell growth in
PNETs. The mainstay of treatment has been the use of somatostatin analogs which bind to somatostatin
receptors controlling both symptoms and cell growth. Sunitinib is a tyrosine kinase inhibitor and inhibits
vasoendothelial derived growth factor (VEGFR) as well as platelet derived growth factor (PDGFR) and
everolimus is an MTOR inhibitor . These are designed to inhibit tumor angiogenesis and or cancer cell
proliferation. Figure 6 mTOR, mammalian target of rapamycin; PDGFR, platelet-derived growth
factor receptor; SSR, somatostatin receptors; VEGFR, vascular endothelial growth receptor.
Reprinted from Endocrinology and Metabolism Clinics of North America, Faivre, S., Sablin, M. P.,
Dreyer, C. and Raymond, E., Novel Anticancer Agents in Clinical Trials for Well-Differentiated